IGC Pharma CALMA (Alzheimer’s Disease with Agitation) This is a trial of the safety and efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease Inclusion Criteria: 60 years of age and above Diagnosis of probable Alzheimer’s Disease Clinically significant agitation, must have a caregiver who can comply with required procedures What […]
SUVEN CTP3S1502HT6 (Alzheimer’s Disease with Agitation) This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer’s type. Inclusion Criteria: 50 years to 9o years Alzheimer’s Dementia (full criteria in link below) What to Expect Study
SUVEN CTP3S1502HT6 Read More »
BIOGEN CELIA In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on
ADCS BENFO-TEAM The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer’s disease. Inclusion Criteria: 50 years to 89 years Mild Cognitive Impairment or Alzheimer’s Disease Availability of a designated study
Research Study Forms 2 Bipolar / Depression Study – RECOVER Study Huntington’s Disease Study – DIMENSION Study Explore More
Research Study Forms Read More »
0XA1 Study This study will test if an investigational medicine (a Medicine being studied) could safely reduce weight in people with obesity or overweight. Inclusion Criteria: Aged 18 to 75 years old Do NOT have diabetes have obesity (BMI of 30 or more) or have overweight (BMI of 27 or more) and a health condition:
Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study: 25 Years to 50 Years (Adult) Sexes Eligible for Study: All Generation HD-2 Link
ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Studies to Assess the Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
STARS and STARS Extension Read More »
